{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:04:06Z","timestamp":1792019046597,"version":"4.4.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,21]],"date-time":"2024-12-21T00:00:00Z","timestamp":1734739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020431","name":"Dartmouth Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020431","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.clml.2024.12.011","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T04:23:41Z","timestamp":1735014221000},"page":"365-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study"],"prefix":"10.1016","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6874-9734","authenticated-orcid":false,"given":"Arvind","family":"Suresh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Wishart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maeen N.","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2733-5947","authenticated-orcid":false,"given":"Raphael A.","family":"Lizcano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parth S.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaroopa","family":"PonnamReddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christi Ann","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryce S.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Moncrief","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7845-3905","authenticated-orcid":false,"given":"Pablo","family":"Martinez-Camblor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy M.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Meehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Hill Jr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.clml.2024.12.011_bib0001","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.jtct.2022.03.006","article-title":"Clinical presentation, risk factors, and outcomes of immune effector cell-associated neurotoxicity syndrome following chimeric antigen receptor T cell therapy: a systematic review","volume":"28","author":"Grant","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.clml.2024.12.011_bib0002","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0003","doi-asserted-by":"crossref","first-page":"18997","DOI":"10.1038\/s41598-020-76055-9","article-title":"Description of neurotoxicity in a series of patients treated with CAR T-cell therapy","volume":"10","author":"Belin","year":"2020","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.clml.2024.12.011_bib0004","doi-asserted-by":"crossref","first-page":"e271","DOI":"10.1016\/j.bbmt.2020.07.031","article-title":"Identification of neurotoxicity after chimeric antigen receptor (CAR) T cell infusion without deterioration in the Immune effector cell encephalopathy (ICE) score","volume":"26","author":"Herr","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"10.1016\/j.clml.2024.12.011_bib0005","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with car t-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.clml.2024.12.011_bib0006","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/brain\/awz053","article-title":"Neurological toxicities associated with chimeric antigen receptor T-cell therapy","volume":"142","author":"Rubin","year":"2019","journal-title":"Brain"},{"issue":"12","key":"10.1016\/j.clml.2024.12.011_bib0007","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s40263-018-0582-9","article-title":"Neurotoxicity associated with CD19-targeted CAR-T cell therapies","volume":"32","author":"Gust","year":"2018","journal-title":"CNS Drugs"},{"issue":"7","key":"10.1016\/j.clml.2024.12.011_bib0008","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"issue":"7","key":"10.1016\/j.clml.2024.12.011_bib0009","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1182\/bloodadvances.2019001305","article-title":"Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial","volume":"4","author":"Maziarz","year":"2020","journal-title":"Blood Adv"},{"issue":"20","key":"10.1016\/j.clml.2024.12.011_bib0010","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0011","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40364-018-0116-0","article-title":"Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy","volume":"6","author":"Wang","year":"2018","journal-title":"Biomark Res"},{"key":"10.1016\/j.clml.2024.12.011_bib0012","unstructured":"Biomarkers emerge for severe neurotoxicity risk after CAR T-cell therapy | OncLive. https:\/\/www.onclive.com\/view\/biomarkers-emerge-for-severe-neurotoxicity-risk-after-car-tcell-therapy. Accessed February 14, 2021."},{"issue":"23","key":"10.1016\/j.clml.2024.12.011_bib0013","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.011_bib0014","doi-asserted-by":"crossref","unstructured":"M\u00f6hn N., Bonda V., Grote-Levi L., et al. Neurological Management and Work-up of Neurotoxicity Associated with CAR T Cell Therapy. Neurological Research and Practice. 2022;4:1-0.","DOI":"10.1186\/s42466-021-00166-5"},{"issue":"7","key":"10.1016\/j.clml.2024.12.011_bib0015","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1097\/CJI.0000000000000241","article-title":"Systematic evaluation of neurotoxicity in children and young adults undergoing CD22 chimeric antigen receptor T-cell therapy","volume":"41","author":"Shalabi","year":"2018","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0016","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.dadm.2014.11.003","article-title":"Practice effects due to serial cognitive assessment: implications for preclinical Alzheimer's disease randomized controlled trials","volume":"1","author":"Goldberg","year":"2015","journal-title":"Alzheimer's Dement (Amst)"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0017","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/blood-2022-162286","article-title":"Inflammatory biomarker clusters are predictive of response and toxicity in large B-cell lymphoma treated with CD19 CAR-T cell therapy","volume":"140","author":"Raj","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.011_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.627764","article-title":"Biomarkers for chimeric antigen receptor T cell therapy in acute lymphoblastic leukemia: prospects for personalized management and prognostic prediction","volume":"12","author":"Hong","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2024.12.011_bib0019","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1110647","article-title":"A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome","volume":"14","author":"Butt","year":"2023","journal-title":"Front Neurol"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1037\/1082-989X.7.1.105","article-title":"Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs","volume":"7","author":"Morris","year":"2002","journal-title":"Psychol Methods"},{"key":"10.1016\/j.clml.2024.12.011_bib0021","series-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988"},{"key":"10.1016\/j.clml.2024.12.011_bib0022","series-title":"IBM SPSS Statistics for Macintosh, Version 27.0","article-title":"Released","year":"2020"},{"key":"10.1016\/j.clml.2024.12.011_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103126","article-title":"Cognition following chimeric antigen receptor T-cell therapy: a systematic review","volume":"140","author":"Kazzi","year":"2023","journal-title":"J Autoimmun"},{"key":"10.1016\/j.clml.2024.12.011_bib0024","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.011_bib0025","article-title":"The association between glucocorticoid administration and the risk of impaired efficacy of axicabtagene ciloleucel treatment: a systematic review","volume":"12","author":"Sun","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2024.12.011_bib0026","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood-2021-146678","article-title":"Impact of corticosteroids on efficacy of BCMA targeted CAR-T therapy in multiple myeloma","volume":"138","author":"Duvalyan","year":"2021","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2024.12.011_bib0027","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0028","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimeric antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.clml.2024.12.011_bib0029","first-page":"930","article-title":"Patient-reported symptom and functioning status during the first 12 months after chimeric antigen receptor T cell therapy for hematologic malignancies","volume":"27","author":"Wang","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.clml.2024.12.011_bib0030","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jtct.2022.05.015","article-title":"Change in patients\u2019 perceived cognition following chimeric antigen receptor T-cell therapy for lymphoma","volume":"28","author":"Barata","year":"2022","journal-title":"Transplantat Cell Ther"},{"issue":"6","key":"10.1016\/j.clml.2024.12.011_bib0031","first-page":"305","article-title":"Change in neurocognitive performance among patients with non-Hodgkin lymphoma in the first year after chimeric antigen receptor T cell therapy","volume":"28","author":"Hoogland","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"9","key":"10.1016\/j.clml.2024.12.011_bib0032","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1093\/neuonc\/noab077","article-title":"Evaluation of mid-term (6-12 months) neurotoxicity in B-cell lymphoma patients treated with CAR T cells: a prospective cohort study","volume":"23","author":"Maillet","year":"2021","journal-title":"Neuro Oncology"},{"issue":"8","key":"10.1016\/j.clml.2024.12.011_bib0033","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jtct.2022.05.004","article-title":"Longitudinal patient reported outcomes with CAR-T cell therapy versus autologous and allogeneic stem cell transplant","volume":"28","author":"Sidana","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.clml.2024.12.011_bib0034","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1056\/NEJMoa2314390","article-title":"Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma","volume":"390","author":"Choi","year":"2024","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.clml.2024.12.011_bib0035","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1182\/blood.2023020571","article-title":"Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells","volume":"142","author":"Karschnia","year":"2023","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.clml.2024.12.011_bib0036","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1182\/blood.2023021860","article-title":"BCMA-CAR T-cell treatment\u2013associated parkinsonism","volume":"142","author":"Gust","year":"2023","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2024.12.011_bib0037","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1182\/blood-2022-165556","article-title":"Predictors and outcomes of Immune effector cell associated neurotoxicity syndrome in patients receiving chimeric antigen receptor T-cell therapy for aggressive B-cell non-hodgkin lymphoma","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2024.12.011_bib0038","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1200\/CCI.21.00023","article-title":"Next-generation implementation of chimeric antigen receptor T-cell therapy using digital health","volume":"5","author":"Banerjee","year":"2021","journal-title":"JCO Clin Cancer Inform"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024480?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265024024480?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:17:28Z","timestamp":1762600648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265024024480"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S2152265024024480"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.011","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel Neurocognitive Testing Tool for Early Neurotoxicity Detection Following Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-cell Therapy: A Pilot Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}